6 June 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Notice of AGM and Directorate Change

Ondine Biomedical Inc. (AIM: OBI) announces that the notice of the Company's 2024 Annual General Meeting ("AGM") and the associated form of proxy have been published today on the Company's website at https://ondinebio.com/investors/reports-documentation/.

Printed copies of the notice of AGM and form of proxy will be posted today to registered shareholders who have elected to receive paper communications.

The Company's AGM will be held virtually at 16:00 BST (08:00 Pacific time) on 28 June 2024. Details of how to access the meeting are contained in the notice of AGM.

All shareholders are encouraged to submit their vote by proxy, well in advance of the meeting. Details of how to vote by proxy are contained in the notice of AGM. All valid proxy votes (whether submitted electronically or in hard copy form) will be included in the poll vote to be taken at the meeting.

The items of business to be voted on at the Meeting are:

·    the re-election of Carolyn Cross, Nicolas G. Loebel, Jean Charest, Jean Duvall, Junaid Bajwa, Michael Farrar, and Craig Tooman as directors of the Company to hold office until the 2025 annual meeting of shareholders or until their successors are elected and qualified, subject to earlier resignation or removal. Non-Independent Director Dr. Simon Sinclair is not standing for re-election to the Board in order to focus on his role as Ondine's Chief Medical Officer, leading the Company's Phase 3 clinical trial efforts. Dr. Sinclair will continue to serve as a Director until the AGM;

·    the re-appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as auditors for the Company for the ensuing year; and

·    to transact such other business as may properly come before the Meeting.

The result of the AGM will be announced after its conclusion and published on the Company's website.

A separate release will be made relating to the announcement of Ondine's full year results to 31 December 2023 and the expected publication of the Company's Annual Report and Accounts.

**ENDS**

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a clinical Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and is approved in Canada and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.